临床肝胆病杂志2026，Vol.42Issue(2)：296-300,5.DOI:10.12449/JCH260208
《2026年欧洲肝病参考网络立场声明:多囊肝病的医疗管理》摘译
An excerpt of medical management of polycystic liver disease:A position statement from the European Reference Network on Hepatological Diseases(2026 edition)
吴文婷 1朱月永1
作者信息
- 1. 福建医科大学附属第一医院肝病中心,福建 350005
- 折叠
摘要
Abstract
In January 2026,the European Reference Network on Hepatological Diseases released a position statement on polycystic liver disease(PLD).Compared with existing diagnosis and treatment recommendations,this statement provides the latest practical guidance on somatostatin analogues as the sole available pharmacological intervention for severe PLD,including clear criteria for eligibility,the criteria for initiation and discontinuation of treatment,and the gaps requiring further research.This statement also defines the criteria for patient selection,treatment goals,and monitoring strategies,and these updates fully reflect the latest clinical evidence and practical needs in the management of PLD.This article gives an excerpt of the key practical recommendations from the statement.关键词
多囊性肝病/生长抑素/欧洲/诊疗准则Key words
Polycystic Liver Disease/Somatostatin/Europe/Practice Guideline引用本文复制引用
吴文婷,朱月永..《2026年欧洲肝病参考网络立场声明:多囊肝病的医疗管理》摘译[J].临床肝胆病杂志,2026,42(2):296-300,5.
